



Tufts Center for the Study of Drug Development

TUFTS UNIVERSITY

Impact REPORT

ANALYSIS AND INSIGHT INTO CRITICAL DRUG DEVELOPMENT ISSUES

Clinical approval success highest for smallest firms among the top 50

Success rates were nearly 30% higher for 30 smallest firms vs. 10 largest

- Small molecules constituted the preponderance (85%) of drugs that entered the clinical pipelines of top 50 pharmaceutical firms in the 1993-04 period.
- Antineoplastic/immunologics were the drugs most frequently taken into clinical testing for all firm size groups within the top 50 companies.
- Among self-originated compounds, CNS was the therapeutic class with the highest share of investigational drugs for each firm size group within the top 50 companies.
- Top 10 firms terminated a higher share of their failures in Phase I than did smaller firms among the 50 largest pharmas.
- Large molecule clinical approval success rates outpaced small molecules by nearly 2:1 across all top 50 pharmas.
- Transitioning compounds from Phase II to Phase III posed a large hurdle across all top companies.